Phase II trial of conversion surgery after apatinib in combination with S-1/oxaliplatin (SOX) for patients with unresectable gastric cancer (Ahead-BG301 trial).

被引：0
|
作者：
Chen, Lin
Zhang, Kecheng
Wei, Bo
Guo, Xin
Xi, Hongqing
Li, Jiyang
Cui, Jianxin
Gao, Yunhe
Liang, Wenquan
Lu, Yixun
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[2] Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.TPS203
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS203
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of S-1 combined with oxaliplatin (SOX) as neoadjuvant chemotherapy for locally advanced gastric cancer
    Chen, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] Phase II trial of S-1 in combination with oxaliplatin (SOx) in previously untreated patients with recurrent or inoperable biliary tract cancer
    Oh, S.
    Lee, G.
    Kim, H.
    Kim, T.
    Kim, H.
    Kang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer
    Seisuke Inada
    Takashi Tomidokoro
    Hiroyuki Fukunari
    Tomomi Sato
    Toru Hatano
    Atsushi Nishimura
    Yasuyuki Kawauchi
    Keiya Nikkuni
    Takeaki Shimizu
    Toshiteru Sato
    Masahiko Yanagi
    Satoru Takahashi
    Hideki Yoshida
    Minoru Sugita
    Tetsuji Hayashi
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 267 - 273
  • [4] Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer
    Inada, Seisuke
    Tomidokoro, Takashi
    Fukunari, Hiroyuki
    Sato, Tomomi
    Hatano, Toru
    Nishimura, Atsushi
    Kawauchi, Yasuyuki
    Nikkuni, Keiya
    Shimizu, Takeaki
    Sato, Toshiteru
    Yanagi, Masahiko
    Takahashi, Satoru
    Yoshida, Hideki
    Sugita, Minoru
    Hayashi, Tetsuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 267 - 273
  • [5] RANDOMIZED PHASE II TRIAL OF S-1 VERSUS S-1 PLUS OXALIPLATIN (SOX) IN PATIENTS WITH GEMCITABINE REFRACTORY PANCREATIC CANCER
    Okusaka, T.
    Ohkawa, S.
    Isayama, H.
    Fukutomi, A.
    Yamaguchi, K.
    Ikeda, M.
    Funakoshi, A.
    Nagase, M.
    Nakamori, S.
    Hamamoto, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 241 - 242
  • [6] Apatinib in combination with S-1 as first-line treatment in patients with advanced gastric cancer: A phase II clinical trial.
    Zhang, Chuantao
    Liu, Zimin
    Zhou, Na
    Zhang, Jianli
    Zhu, Jingjuan
    Lv, Hongying
    Li, Tianjun
    Hou, Helei
    Liu, Dong
    Cong, Jing
    Jiang, Man
    Liu, Kewei
    Cui, Zhumei
    Zhou, Yanbing
    Zhang, Xiaochun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [7] Phase II study of conversion therapy using S1/paclitaxel chemotherapy plus apatinib in unresectable gastric cancer (Ahead-G325 trial).
    Cheng, Xiangdong
    Xu, Zhiyuan
    Du, Yian
    Hu, Ping
    Yu, Guofa
    Hu, Conggang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [8] Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer
    Zaisheng Ye
    Yi Zeng
    Shenghong Wei
    Yi Wang
    Zhitao Lin
    Shu Chen
    Zhiwei Wang
    Shanshan Chen
    Luchuan Chen
    BMC Cancer, 21
  • [9] Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer
    Ye, Zaisheng
    Zeng, Yi
    Wei, Shenghong
    Wang, Yi
    Lin, Zhitao
    Chen, Shu
    Wang, Zhiwei
    Chen, Shanshan
    Chen, Luchuan
    BMC CANCER, 2021, 21 (01)
  • [10] Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer
    Narahara, Hiroyuki
    Fujitani, Kazumasa
    Takiuchi, Hiroya
    Sugimoto, Naotoshi
    Inoue, Kentaro
    Uedo, Noriya
    Tsukuma, Hideaki
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    Taguchi, Tetsuo
    ONCOLOGY, 2008, 74 (1-2) : 37 - 41
12345